Brands
Naveen Kokkanti promoted to director – devOps at Nasdaq
Tech leader steps up to steer innovation and modernise systems
BENGALURU: Naveen Kokkanti has been elevated to director – devOps at Nasdaq, marking a defining moment in his 14 year journey through the fast evolving world of digital transformation.
Based in Bengaluru, Kokkanti moves into the role after a short but impactful stint as lead devOps engineer at the global exchange operator. In his new position, he will focus on driving innovation, sharpening operational efficiency and reinforcing the organisation’s technology backbone.
For Kokkanti, the promotion reflects more than a change in title. It crowns over a decade of building, migrating and modernising enterprise systems across some of the biggest names in technology and consulting.
Before joining Nasdaq in 2025, he spent four years at Deloitte Consulting as senior consultant, where he worked extensively on large scale cloud and data transformations. His work ranged from migrating legacy data applications to AWS and implementing unity catalog governance frameworks, to designing multi cloud Databricks lakehouse strategies. He was also part of Deloitte’s Databricks alliance core team, contributing to go to market initiatives and publishing technical whitepapers on migration and architecture best practices.
Earlier roles at Virtusa and Infosys saw him lead cloud migrations, design secure infrastructure environments and manage enterprise grade AWS ecosystems. At Infosys, he led a team of engineers while overseeing everything from VPC architecture and IAM policies to disaster recovery, security hardening and cost optimisation.
His career began with hands on infrastructure and support roles at Micro Focus, Cerner Corporation and Dell Technologies, where he developed a strong foundation in systems engineering, virtualisation and enterprise IT operations.
Across roles, a consistent theme emerges. Kokkanti thrives at the intersection of cloud, data and governance. From Terraform and AWS to Databricks and enterprise devOps frameworks, his skillset reflects the growing demand for leaders who can translate complex infrastructure into scalable, secure and business ready platforms.
At Nasdaq, that blend of technical depth and leadership experience is set to play a key role as the organisation continues to evolve its global technology infrastructure. For Kokkanti, the promotion is not just about moving up. It is about building forward.
Brands
Sun Pharma launches ‘Heart ke Liye 8’ heart health drive
New campaign urges daily habits to build a stronger heart
MUMBAI: Sun Pharmaceutical Industries Limited has launched its ‘Heart ke Liye 8 – Making India Heart Strong’ campaign, urging Indians to prioritise heart health through simple, consistent daily actions.
The initiative comes at a crucial time. Cardiovascular disease accounts for nearly one-fifth of global heart-related deaths, with Indians often affected almost a decade earlier than many Western populations. The campaign reinforces a clear message: heart health is not built overnight, but through everyday choices.
Speaking on the launch, Sun Pharma senior vice president, marketing and sales Shailesh Joshi, said the company believes prevention is just as important as treatment. He noted that the campaign aims to spark regular conversations around heart health and encourage people to adopt small habits that can make a lasting difference.
At the centre of the campaign is the ‘Heart-strong Man’, a relatable and optimistic character symbolising a well-cared-for heart. The tone remains positive and practical, encouraging individuals to take charge of their wellbeing without fear. The campaign film has been created in multiple Indian languages to ensure wider accessibility.
The initiative is anchored around eight essential pillars of heart health, including eating better, staying physically active, managing weight, keeping blood pressure, blood sugar and cholesterol in check, avoiding tobacco, going for regular health check-ups, managing stress, and getting quality sleep.
Beyond awareness, the company’s Making India Heart Strong initiative takes an integrated approach to prevention and response. Sun Pharma organises around 10,000 heart screening camps annually, screening over 1.2 lakh people each year.
In addition, it conducts CPR training for more than 1.5 lakh individuals annually to strengthen emergency preparedness, while also investing in evidence generation to improve risk assessment and patient outcomes.
Its patient education efforts further extend to more than 15 million individuals every year through in-clinic print materials and awareness programmes, contributing to a broader, long-term effort to reduce the cardiovascular disease burden in India.
